TY - JOUR
T1 - New frontiers in nanotechnology for cancer treatment
AU - Alexis, Frank
AU - Rhee, June Wha
AU - Richie, Jerome P.
AU - Radovic-Moreno, Aleksandar F.
AU - Langer, Robert
AU - Farokhzad, Omid C.
N1 - Funding Information:
This work was supported by NIH/NCI CA119349, NIH/NIBIB EB003647, and a development grant from the DFHCC Prostate SPORE.
PY - 2008/1
Y1 - 2008/1
N2 - Nanotechnology is a field of research at the crossroads of biology, chemistry, physics, engineering, and medicine. Design of multifunctional nanoparticles capable of targeting cancer cells, delivering and releasing drugs in a regulated manner, and detecting cancer cells with enormous specificity and sensitivity are just some examples of the potential application of nanotechnology to oncological diseases. In this review we discuss the recent advances of cancer nanotechnology with particular attention to nanoparticle systems that are in clinical practice or in various stages of development for cancer imaging and therapy.
AB - Nanotechnology is a field of research at the crossroads of biology, chemistry, physics, engineering, and medicine. Design of multifunctional nanoparticles capable of targeting cancer cells, delivering and releasing drugs in a regulated manner, and detecting cancer cells with enormous specificity and sensitivity are just some examples of the potential application of nanotechnology to oncological diseases. In this review we discuss the recent advances of cancer nanotechnology with particular attention to nanoparticle systems that are in clinical practice or in various stages of development for cancer imaging and therapy.
KW - Cancer diagnosis
KW - Cancer therapy
KW - Nanocarriers
KW - Targeting molecules
UR - http://www.scopus.com/inward/record.url?scp=37649015048&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2007.03.017
DO - 10.1016/j.urolonc.2007.03.017
M3 - Artículo de revisión
C2 - 18190835
AN - SCOPUS:37649015048
SN - 1078-1439
VL - 26
SP - 74
EP - 85
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 1
ER -
